All In Biotech

Drug Trial Radar · NCT04890795

A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer

A Single Arm, Open, Non Randomized, Phase Ib / IIA Study to Evaluate the Safety and Preliminary Efficacy of AL8326 in the Treatment of Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: May 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

237

Planned (sponsor's estimate)

Start

Oct 19, 2020

Primary completion

Sep 2021

Study completion Sep 2021

Sponsor

Sponsor type
Industry
First posted
May 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Based on indicators such as 24 week progression free survival (24 weeks PFS) in small cell lung cancer (SCLC) patients without disease progression after first-line platinum containing chemotherapy, objective response rate (ORR) in SCLC patients with recurrence or progression after first-line platinum containing chemotherapy, and orr in SCLC patients with recurrence or progression after second-line and above treatment,Evaluation of the effectiveness of al8326 monotherapy in small cell lung cancer.

Conditions

  • Small Cell Lung Cancer

Interventions

  • AL8326 tabletsDrug

    10mg/tablet;Oral administration, once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (Group A) 24 weeks progression free survival (24 weeks PFS)Time frame: Every 2 cycles(each cycle is 28--days)
  2. (Group B and C) Objective response rate (ORR)Time frame: Every 2 cycles(each cycle is 28--days)

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • The first affiliated hospital of bengbu medical college

    Bengbu, Anhui, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • General Hospital of Eastern Theater Command

    Nanjing, Jiangsu, China · Recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Recruiting

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.